
Jan 22 (Reuters) - Vaxcyte Inc PCVX.O:
VAXCYTE ADVANCES ADULT AND INFANT PROGRAMS FOR VAX-31, A POTENTIAL BEST-IN-CLASS, NEXT-GENERATION PNEUMOCOCCAL CONJUGATE VACCINE
VAXCYTE: VAX-31 ADULT PHASE 3 NONINFERIORITY TRIAL (OPUS-1) CONTINUES TO ENROLL SUBJECTS, WITH TOPLINE DATA EXPECTED IN FOURTH QUARTER OF 2026
VAXCYTE: EXPECTS TO REPORT TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITY DATA FROM BOTH OPUS-2 AND OPUS-3 PHASE 3 STUDIES IN FIRST HALF OF 2027